NOVAMIND REDDIT TRIAL

MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success Interested in reading the article? Click here: 👇 In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.” In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.įurthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.” It does not appear that this patient had any troubles once the effects wore off. Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. The average reduction in the STAI was 16.2 points. This compared to only 9% of patients in the placebo arm reaching that 30% level. The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. The results were very positive, though perhaps not paradigm shifting - yet. Patients received 200 µg (micrograms) of LSD, which is considered a large dose. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today. In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results. The Psychedelic Investor: Spotlight: us on The Psychedelic Investor will be changing its name to PSYC Business very soon. Join our Newsletter (scroll to the bottom of the page and sign up): Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:

Novamind reddit